肝硬変とその合併症の管理のためのプロバイオティクス
Junxiu Chen1, Haonan Zhao1, Nahum Méndez-Sánchez2
1Department of Gastroenterology, General Hospital of Northern Theater Command, Teaching Hospital of Shenyang Pharmaceutical University, Shenyang, China; Department of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang, China.
Archives of medical research
|September 6, 2025
まとめ
プロバイオティクスは腸内微生物のバランスを改善することで 肝硬変とその合併症の管理に役立ちます このレビューでは,肝臓の健康と腸-肝臓軸の調節に対する潜在的な利点について考察します.
科学分野:
- 胃腸科と肝臓科
- 微生物群の研究
- 翻訳医学
背景:
- 肝硬変は慢性肝疾患の 進行段階であり 肝臓脳病やアシテスのような重篤な合併症を 引き起こします
- 腸内微生物失調症は肝硬変の患者でよく見られるもので,腸肝軸に影響します.
- 腸肝軸は肝硬変の発生と進行に 重要な役割を果たします
研究 の 目的:
- 肝硬変の管理におけるプロバイオティクスの潜在的な有効性を包括的に検討する.
- 肝硬変に関連する合併症を緩和するプロバイオティクスの役割を探る
- 肝臓疾患の管理に 腸内微生物をターゲットに 洞察を提供するためです
主な方法:
- プロバイオティクス,肝硬変,腸内微生物に関する研究の文献レビュー.
- 肝疾患における腸肝軸に関する既存の研究の分析
- 肝硬変とその合併症に対するプロバイオティクスの介入に関する証拠のまとめ
主要な成果:
- 腸内微生物障害は肝硬変の発生と進行と密接に関連しています.
- プロバイオティクスは 肝硬変患者の腸内微生物群を 調節する可能性を 示しています
- 肝硬変に伴う合併症の管理に 益生菌が役立つという証拠があります
結論:
- プロバイオティクスは肝硬変の治療に 有望な治療戦略です
- プロバイオティクスを用いて 腸内微生物群をターゲットにすることで 肝臓疾患の治療に 新たな機会が生まれます
- 肝硬変の治療におけるプロバイオティクスの利点を完全に解明するには,さらなる研究が必要である.
さらに関連する動画
関連する概念動画
01:26Diseases of the Liver and Gallbladder
957
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
957
01:28Esophageal Varices-II: Clinical Features and Management
133
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
133
01:29Inflammatory Bowel Disease IV: Pharmacological Management
177
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
177
01:23Gastritis III: Clinical Manifestations and Management
462
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
462
01:21Drugs for Treatment of Constipation-Predominant IBS
322
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
322
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
407
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
407